Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
Roivant (Nasdaq: ROIV) has scheduled a conference call and webcast for Monday, August 11, 2025, at 8:00 a.m. ET to discuss its financial results for the first quarter ended June 30, 2025, and provide a business update. Investors can access the call by registering through an online link, and presentation materials will be available in the Investors section of Roivant's website. The webcast recording will be archived on the company's website following the event.
Roivant (Nasdaq: ROIV) ha programmato una conference call e un webcast per lunedì 11 agosto 2025, alle 8:00 ET per discutere i risultati finanziari del primo trimestre terminato il 30 giugno 2025 e fornire un aggiornamento aziendale. Gli investitori possono partecipare alla chiamata registrandosi tramite un link online, e i materiali della presentazione saranno disponibili nella sezione Investitori del sito web di Roivant. La registrazione del webcast sarà archiviata sul sito dell'azienda dopo l'evento.
Roivant (Nasdaq: ROIV) ha programado una llamada de conferencia y una transmisión web para el lunes 11 de agosto de 2025, a las 8:00 a.m. ET para discutir los resultados financieros del primer trimestre finalizado el 30 de junio de 2025 y proporcionar una actualización comercial. Los inversores pueden acceder a la llamada registrándose a través de un enlace en línea, y los materiales de la presentación estarán disponibles en la sección de Inversores del sitio web de Roivant. La grabación del webcast se archivará en el sitio web de la empresa después del evento.
Roivant (나스닥: ROIV)는 2025년 8월 11일 월요일 오전 8시 ET에 2025년 6월 30일 종료된 1분기 재무 결과 및 사업 업데이트를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 예정했습니다. 투자자들은 온라인 링크를 통해 등록하여 콜에 참여할 수 있으며, 발표 자료는 Roivant 웹사이트의 투자자 섹션에서 제공됩니다. 웹캐스트 녹화는 행사 후 회사 웹사이트에 아카이브될 예정입니다.
Roivant (Nasdaq : ROIV) a programmé une conférence téléphonique et un webcast pour le lundi 11 août 2025 à 8h00 ET afin de discuter des résultats financiers du premier trimestre clos le 30 juin 2025 et de fournir une mise à jour commerciale. Les investisseurs peuvent accéder à l'appel en s'inscrivant via un lien en ligne, et les supports de présentation seront disponibles dans la section Investisseurs du site web de Roivant. L'enregistrement du webcast sera archivé sur le site de l'entreprise après l'événement.
Roivant (Nasdaq: ROIV) hat eine Telefonkonferenz und einen Webcast für Montag, den 11. August 2025, um 8:00 Uhr ET angesetzt, um die Finanzergebnisse für das am 30. Juni 2025 endende erste Quartal zu besprechen und ein Unternehmensupdate zu geben. Investoren können an dem Anruf teilnehmen, indem sie sich über einen Online-Link registrieren, und Präsentationsmaterialien werden im Investor-Bereich der Roivant-Website verfügbar sein. Die Aufzeichnung des Webcasts wird nach der Veranstaltung auf der Unternehmenswebsite archiviert.
- None.
- None.
BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and provide a business update.
To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.
About Roivant
Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit www.roivant.com.
Roivant Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
FAQ
When is Roivant (ROIV) reporting Q1 2025 earnings?
How can investors access Roivant's Q1 2025 earnings call?
What period will Roivant's upcoming earnings report cover?
Will Roivant's Q1 2025 earnings call be available for replay?
